Steve Otieno, MD
Medical Oncology · Memphis, TNNPI 1932587128
Payments from drug & device makers
Across 32 payments — averaging $52.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$226
- Seagen Inc.$212
- Myriad Genetic Laboratories, Inc.$169
- Lilly USA, LLC$164
- Novocure Inc.$141
- Takeda Pharmaceuticals U.S.A., Inc.$137
- plus $645 from 14 others
What the payments were for
- Consulting fees$1046%
- Food & beverage$1,25374%
- Education$33620%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 3 | $226 |
| Seagen Inc. | 5 | $212 |
| Myriad Genetic Laboratories, Inc. | 1 | $169 |
| Lilly USA, LLC | 3 | $164 |
| Novocure Inc. | 1 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $137 |
| Acrotech Biopharma Inc. | 1 | $104 |
| Dova Pharmaceuticals | 1 | $100 |
| BTG International Inc. | 1 | $84 |
| Amgen | 1 | $73 |
| Adaptive Biotechnologies Corporation | 1 | $70 |
| Merck | 3 | $45 |
| Sanofi | 1 | $31 |
| Immunocore Limited | 1 | $29 |
| AstraZeneca | 2 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Novo Nordisk | 1 | $16 |
| Array Biopharma Inc | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,693 in reported general payments places this provider in the 20th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 19 | $315,337 |
| YonsaAbiraterone Acet,submicronized | 11 | $104,739 |
| EliquisApixaban | 56 | $42,106 |
| Imatinib Mesylate | 23 | $4,063 |
| Oxycodone Hcl | 88 | $912 |
| Mirtazapine | 40 | $754 |
| Ondansetron OdtOndansetron | 25 | $720 |
| LoperamideLoperamide Hcl | 40 | $517 |
| Anastrozole | 24 | $435 |
| Letrozole | 33 | $314 |
| Ondansetron Hcl | 26 | $283 |
| Potassium Chloride | 49 | $254 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 21 | $248 |
| Duloxetine Hcl | 14 | $205 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $180 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Memphis
- Lindsey LandsMemphis$72K
- David HayesMemphis$6K
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Gregory VidalGermantown$12.5M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Daniel VaenaGermantown$5M
- Ari VanderwaldeGermantown$4.9M
- Gina VaccaroCookeville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.